Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03109041 · ClinicalTrials.gov registry record · Phase 1
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
A Phase 1 study, sponsored by CivaTech Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03109041: Completed Phase 1 study, sponsored by CivaTech Oncology.
NCT03109041 is a Phase 1 study that has completed, run by CivaTech Oncology. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03109041, a Phase 1 study, has completed, sponsored by CivaTech Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a Phase I evaluation to determine the usefulness of a new brachytherapy device that utilizes active components (Palladium-103) of standard devices in a novel configuration. This study may benefit resectable pancreatic cancer patients by reducing the radiation dose to adjacent critical structures, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.
Primary Outcome
Patients with resectable pancreatic cancer who are undergoing pancreatic cancer resection will be monitored for safety \& toxicities graded using the CTCAE 4.0 scale.
Interventions
- DEVICE CivaSheet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-09-06 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 1 |
What the finished NCT03109041 record still lists
NCT03109041 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which CivaSheet is the first listed.
NCT03109041 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03109041 about?
NCT03109041 is a clinical study titled "Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source". This is a Phase I evaluation to determine the usefulness of a new brachytherapy device that utilizes active components (Palladium-103) of standard devices in a novel configuration. This study may benefit resectable pancreatic cancer patients by reducing the radiation dose to adjacent critical struct...
What is the current status of trial NCT03109041?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2017-09-06. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT03109041?
The interventions under investigation include: CivaSheet (DEVICE).
Who is sponsoring clinical trial NCT03109041?
This trial is sponsored by CivaTech Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03109041's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI